Protocol Ledger

NCT06984588 · Phase II/III · ACTIVE NOT RECRUITING

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected

Interventional Phase II/III clinical trial protocol NCT06984588 sponsored by TJ Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-28 Enrollment: 450 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06984588
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)450 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06984588
Protocol FieldVerified Registry Value
NCT IdentifierNCT06984588
Consolidated Lead SponsorTJ Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment450 participants (ESTIMATED)
Registered Start Date2024-03-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06984588
Hospital Research SiteLocationSite Profile
The Third Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
Chongqing University Cancer HospitalChongqing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI